Regulatory Focus™ > News Articles > Perspective: Evaluating Regulator Risk for Comparator Drug Products

Posted 01 May 2011 | By Cesar Medina, MBA, RACFerno Alvarez-Nunex, PhD

Perspective: Evaluating Regulator Risk for Comparator Drug Products

Evaluating risks and developing mitigation strategies have become common industry practices in drug development. Regulatory agencies have adopted risk-based approaches in quality management, pharmaceutical development and postmarket surveillance of medicinal products.1-4

 

© 2022 Regulatory Affairs Professionals Society.

Discover more of what matters to you

No taxonomy
No data found